Critical Assessment of In Vitro Screening of α-Glucosidase Inhibitors from Plants with Acarbose as a Reference Standard.

Postprandial hyperglycemia is treated with the oral antidiabetic drug acarbose, an intestinal -glucosidase inhibitor. Side effects of acarbose motivated a growing number of screening studies to identify novel -glucosidase inhibitors derived from plant extracts and other natural sources. As "gold standard", acarbose is frequently included as the reference standard to assess the potency of these candidate -glucosidase inhibitors, with many outperforming acarbose by several orders of magnitude. The results are subsequently used to identify suitable compounds/products with strong potential for efficacy. However, most -glucosidase inhibitor screening studies use enzyme preparations obtained from nonmammalian sources (typically ), despite strong evidence that inhibition data obtained using nonmammalian -glucosidase may hold limited value in terms of identifying -glucosidase inhibitors with actual hypoglycemic potential. The aim was to critically discuss the screening of novel -glucosidase inhibitors from plant sources, emphasizing inconsistencies and pitfalls, specifically where acarbose was included as the reference standard. An assessment of the available literature emphasized the cruciality of stating the biological source of -glucosidase in such screening studies to allow for unambiguous and rational interpretation of the data. The review also highlights the lack of a universally adopted screening assay for novel -glucosidase inhibitors and the commercial availability of a standardized preparation of mammalian -glucosidase.